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Background: Axitinib, a selective and potent tyrosine kinase inhibitor of vascular endothelial 
growth factor receptors, was available to patients from Canada and Australia, prior to regulatory 
approval of axitinib in these countries, for treatment of clear-cell metastatic renal cell carcinoma 
(mRCC) after failure of one prior systemic regimen.
Methods: This single-arm, open-label study of axitinib evaluated the efficacy, safety, and 
quality of life (QoL) in patients with mRCC whose disease progressed after one prior systemic 
first-line regimen. Primary objective was objective response rate evaluated per Response Evalu-
ation Criteria in Solid Tumors (RECIST) and Choi criteria. Progression-free survival, overall 
survival, safety, and QoL were secondary end points. Due to the small study size, analyses 
comprised of descriptive statistics.
Results: Fifteen patients were recruited, five from Canada and ten from Australia, over a 
limited recruitment period. Thirteen patients received sunitinib as prior therapy. All patients 
had clear-cell carcinoma, eleven had prior nephrectomy. Liver, lung, and lymph nodes were 
the most frequent sites of metastases; one patient had brain metastasis. Median time on axi-
tinib was 118.0 days (range: 3.5–645.0 days); estimated survival probability at 12 months 
was 57.8%. Two (13.3%) patients had objective responses per RECIST versus nine (60.0%) 
per Choi criteria. Six patients had progressive disease based on RECIST versus three per 
Choi criteria. Nine (60.0%) events of progression or death occurred by the end of study, and 
three patients continued to receive the study drug. Fatigue (33%) and diarrhea (20%) were 
the most common grade $3 all-causality, treatment-emergent adverse events. The mean 
change in European Quality of Life – 5 Dimensions score from baseline to end of treatment 
was −0.0837.
Conclusion: The small number of patients and lack of a comparator arm limit the ability to 
draw definitive conclusions; however, safety and efficacy profiles of axitinib were consistent 
with reports from previous studies in patients with mRCC, and patients generally maintained 
QoL. The sizeable difference observed in objective response rate by RECIST versus Choi 
criteria merits further research.
Keywords: RECIST, objective response rate, metastatic, vascular endothelial growth factor 
receptor inhibitor
Introduction
Kidney cancer accounts for 2%–3% of all adult cancers and was newly diagnosed in 
337,860 people in 2012 worldwide, resulting in .143,000 deaths.1 Approximately 
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90% of kidney cancers are renal cell carcinoma (RCC) and 
85% of those are clear-cell tumors.2 Treatment of metastatic 
RCC (mRCC) has been transformed in the last decade with 
the development of agents that target tumor angiogenesis 
by inhibiting either the vascular endothelial growth factor 
(VEGF) pathway3–13 or the mammalian target of rapamycin 
pathway.14,15
Axitinib (Inlyta®; Pfizer Inc, New York, NY, USA16) is 
an oral, potent, and selective second-generation inhibitor of 
VEGF receptors 1, 2, and 3.17 In the global Phase III AXIS 
trial, axitinib demonstrated superior efficacy over sorafenib 
in patients with mRCC after failure of one prior systemic 
therapy.18 Median progression-free survival (PFS) was 
6.7 months (95% CI: 6.3–8.6) with axitinib compared with 
4.7 months (95% CI: 4.6–5.6) with the active comparator, 
sorafenib (hazard ratio, 0.665; 95% CI: 0.544–0.812, one-
sided P,0.0001). Axitinib is approved in 66 countries, 
including the USA,16 European Union, Japan, and South 
Korea, for treatment of previously treated patients with 
advanced RCC.
Tumor response to treatment has been traditionally evalu-
ated using Response Evaluation Criteria in Solid Tumors 
(RECIST), which monitors changes in tumor size.19 With 
the introduction of targeted therapies, the use of RECIST 
criteria has often been questioned. It is based on tumor size 
measurements, whereas many targeted agents do not neces-
sarily change tumor size but decrease tumor vascularization 
and cause necrosis; evaluation based on only size can lead 
to underestimation of tumor response to treatment. The 
Choi criteria were therefore introduced.20 These criteria 
evaluate changes in tumor size and density and were found 
to be effective in assessing early response to treatment in 
gastrointestinal stromal tumors (GISTs),20–23 hepatocellular 
carcinoma,24,25 and high-risk soft tissue sarcoma.26 Choi 
criteria were also valuable in early detection of response to 
sunitinib in patients with mRCC.27
We report results from a compassionate use study that 
provided access to axitinib treatment to Canadian and 
Australian patients with mRCC whose disease progressed 
after one prior systemic therapy. Axitinib became com-
mercially available in Canada and Australia while the study 
was ongoing. The primary objective of this study was to 
determine overall (complete + partial) objective response rate 
(ORR) per RECIST criteria, Version 1.1. Choi criteria were 
also used to assess response, and the results were compared 
with RECIST. Secondary objectives included assessment of 
PFS, overall survival (OS), safety, and quality of life (QoL) 
measures.
Methods
patients
Patients included in this study were men and nonpregnant, 
nonlactating women aged 18 years or older with histologically 
or cytologically confirmed mRCC with a component of 
clear-cell subtype who failed a prior single line of therapy 
with either a single agent or a combination of any of the 
following agents: interleukin-2, interferon, bevacizumab, 
sunitinib, pazopanib, tivozanib, temsirolimus, or everolimus. 
Patients had evidence of disease, with at least one measur-
able lesion as per RECIST Version 1.1; Eastern Cooperative 
Oncology Group performance status (ECOG PS) 0 or 1; 
adequate renal, hepatic, and hematologic organ function; life 
expectancy of at least 12 weeks; at least 2 weeks since the 
end of prior systemic treatment (4 weeks for bevacizumab 
plus interferon-α), radiotherapy, or surgical procedure; and 
no uncontrolled hypertension (.140/90 mmHg), based on 
two baseline blood pressure (BP) readings taken at least 
1 hour apart.
Key exclusion criteria included having major bowel-
penetrating surgery within ,4 weeks of starting the study 
treatment; active peptic ulcer disease in the past 6 months 
or active gastrointestinal bleeding in the past 3 months; 
current or anticipated use of potent inhibitors of cytokine 
P450 (CYP) 3A4/5 or inducers of CYP3A4/5 or CYP1A2; 
anticoagulant therapy with oral vitamin K antagonists; 
evidence of symptomatic or untreated brain metastases, 
spinal cord compression, carcinomatous meningitis, or 
active seizure disorder; myocardial infarction, uncontrolled 
angina, coronary/peripheral artery bypass graft, symptomatic 
congestive heart failure, cerebrovascular accident or tran-
sient ischemic attack, or aneurism at risk of rupture within 
12 months prior to study drug administration; or history of 
a malignancy other than RCC.
Study design
This was a single-arm, open-label, multicenter study of axi-
tinib in patients with mRCC whose disease progressed after 
one prior systemic first-line regimen containing single or 
combination therapy with a cytokine, VEGF, or mammalian 
target of rapamycin inhibitor or those who discontinued due to 
prohibitive toxicity. The study was conducted in two countries: 
Australia (three centers) and Canada (one center).
The study protocol, amendments, and informed consent 
forms were reviewed and approved by the institutional review 
board or independent ethics committee at each study center 
(Table S1). The study was conducted in accordance with the 
protocol, International Conference on Harmonization Good 
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Clinical Practice guidelines, and applicable local regulatory 
requirements and laws. Informed consent was obtained from 
each patient prior to study initiation. This trial is registered 
on ClinicalTrials.gov, identifier NCT01473043.
Treatment
Axitinib was taken orally with or without food at starting 
dose of 5 mg twice daily on a continuous basis, as established 
previously.18 Dose titration was based on BP response and 
toxicity experienced as previously described.18 Study treat-
ment was administered in cycles of 4 weeks in duration.
assessments
Baseline tumor assessments included computed tomography/
magnetic resonance imaging scans of the brain, chest, abdo-
men, pelvis, and bone. Computed tomography/magnetic 
resonance imaging scans (except brain) were repeated every 
8 weeks. Data on best response, PFS, and time to progression 
were collected according to RECIST Version 1.1.28 Bone 
or brain scans were only required if clinically indicated. 
Responses were evaluated by the respective radiologist 
at each site. Tumor response was also assessed based on 
Choi criteria using the same target lesions used for baseline 
estimation as per RECIST. The radiologists in each center 
received training in the interpretation of Choi criteria. Den-
sity measurements were performed by drawing a perimeter 
around the target lesion and documenting the pixel value 
in Hounsfield Units. After measuring the densities of all 
identified target lesions, a total sum value of densities was 
recorded at baseline and was used as a reference point 
to assess response on follow-up measurements. Assess-
ment of tumor response per Choi criteria was as described 
previously,20 where complete response is based on size cri-
teria only and partial response is based on a decrease $15% 
in density of the sum value from baseline (Table 1). 
Per protocol, patients were to be followed-up for survival 
every 3 months for up to 2 years after last patient/first visit; 
however, follow-up was only completed until the end date 
of the study, March 12, 2014.
Safety was assessed in all patients by adverse events 
(AEs) graded according to National Cancer Institute Com-
mon Terminology Criteria for Adverse Events Version 4.0. 
All observed or volunteered AEs (serious and nonserious), 
their severity, and relationship to the investigational drug 
were reported throughout the study. Physical examination, 
including the assessment of all body systems (including 
neurologic assessment), the measurement of body weight, 
height, pulse, and temperature, and the assessment of ECOG 
PS was performed at baseline, on day 1 (if .7 days since 
baseline), every 4 weeks, and at end of study treatment. 
A single 12-lead electrocardiogram was performed on all 
patients at screening. Additional electrocardiograms were 
performed as clinically indicated.
BP was monitored at each clinic visit and at least twice 
daily at home by the patient prior to taking each dose of 
axitinib. Patients were instructed to inform their doctor 
immediately if systolic BP was .150 mmHg, diastolic 
BP .100 mmHg, or if symptoms perceived to be related 
to elevated BP (eg, headache and visual disturbance) 
developed. Laboratory tests for hematology, chemistry, and 
biochemistry were performed at baseline, day 1 (if .7 days 
since baseline), every 4 weeks, and end of study treatment. 
Thyroid function tests (free triiodothyronine, free thyroxine, 
and thyroid-stimulating hormone) were performed at base-
line (cycle 1 day 1, predose), cycle 1 day 15, cycle 2 day 1, 
cycle 3 day 1, cycle 4 day 1, cycle 5 day 1, and beginning 
with cycle 6 day 1, every 8 weeks thereafter.
Patient-reported outcomes were assessed using the 
European Quality of Life – 5 Dimensions (EQ-5D)24 ques-
tionnaire administered on cycle 1 day 1 before dosing and 
Table 1 Comparison of Choi and reCiST 1.1 criteria
Response Definition
Choi criteria20 RECIST 1.128
Complete response Disappearance of all lesions
no new lesions
Disappearance of all target lesions, all nodal 
lesions have short axis ,10 mm
partial response a decrease in size $10% or a decrease in tumor 
attenuation (HU) $15% on CT
no new lesions
no obvious progression of nonmeasurable disease
$30% decrease in the sum of diameters from 
baseline sum diameters
progressive disease an increase in tumor size $10% and does not 
meet criteria of pr by tumor attenuation on CT
new lesions
$20% increase in the smallest sum of diameters 
as reference with an absolute increase of $5 mm
Stable disease Does not meet the above criteria Does not meet the above criteria
Abbreviations: reCiST, response evaluation Criteria in Solid Tumors; CT, computed tomography; pr, partial response.
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before any other clinical assessments, then every 4 weeks 
while on study, at end of study treatment/withdrawal, and at 
follow-up (28 days after last dose). EQ-5D summary results 
were derived by combining one level from each of the five 
EQ-5D dimensions (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression) and converting 
to a single summary index. Possible EQ-5D scores range 
from −0.594 to 1, with low scores representing a higher 
level of dysfunction. For the EuroQol Visual Analogue 
Scale, patients rated their overall health status from 0 (worst 
imaginable) to 100 (best imaginable).
Statistical analyses
The primary efficacy end point was ORR as assessed by the 
investigator. ORR was defined as the proportion of patients 
with confirmed complete response or confirmed partial 
response according to RECIST.19 Confirmed responses were 
those that persisted on repeat-imaging study at least 4 weeks 
after the initial documentation of response. Patients who 
did not have on-study radiographic tumor reevaluation or 
who died, progressed, or discontinued for any reason prior 
to reaching a complete or partial response were counted as 
nonresponders in the assessment of ORR. A patient who 
initially met the criteria for a partial response and then sub-
sequently confirmed as a complete responder was assigned 
a best response of complete response. Response status 
was also defined and summarized based on Choi criteria 
in a similar manner as for the response status defined by 
RECIST.20
Secondary end points included PFS, defined as the time 
from date of first dose of study drug to first documentation 
of objective tumor progression or death. Clinical benefit rate 
was defined as the proportion of patients with confirmed com-
plete response, confirmed partial response, or stable disease 
for $8 weeks to treatment failure. OS was defined as the time 
from date of first dose of study drug to first documentation 
of death due to any cause.
Efficacy, safety, and patient-reported outcomes were 
analyzed in the full analysis set (ie, all enrolled patients who 
received at least one dose of axitinib during the study period). 
This study was noncomparative, and no inferential statisti-
cal analyses were planned. Analyses consisted of descrip-
tive statistics and corresponding 95% two-sided CIs when 
appropriate. PFS and OS were summarized using Kaplan–
Meier method and displayed graphically. The median event 
time was provided for PFS and OS. All data summaries and 
tabulations were prepared by using SAS® Version 9.2 (SAS 
Institute Inc., Cary, NC, USA).
Results
patients and treatment
Between March 1, 2012, and March 12, 2014, 15 previously 
treated patients with mRCC (five from one center in Canada 
and ten from three centers in Australia) were enrolled in the 
study and included in the full analysis set. Demographic and 
baseline characteristics are presented in Table 2. The mean 
age of patients was 55.1 years, and 12 (80.0%) patients 
were ,65 years of age. Seven (46.7%) patients had ECOG 
PS 0 and eight (53.3%) had ECOG PS 1. Eleven (73.3%) 
patients had previous surgery for nephrectomy. Prior 
treatment regimens included sunitinib-containing (n=13), 
pazopanib-containing (n=1), and tivozanib-containing 
(n=1) therapies. Median time on axitinib was 118.0 days 
Table 2 patient demographics and baseline characteristics
Characteristic Axitinib 
(N=15)
age, years
Mean (SD) 55.1 (9.86)
Median (range) 54.0 (33–71)
age, years
,65 12 (80.0)
$65 3 (20.0)
Sex
Male 11 (73.3)
Female 4 (26.7)
race
White 15 (100)
eCOG pSa
0 7 (46.7)
1 8 (53.3)
MSKCC risk group (no of risk factors)b
Favorable (0) 4 (26.7)
intermediate (1) 6 (40.0)
poor (2–3) 5 (33.3)
Current stage
Stage iii 1 (6.7)
Stage iV 14 (93.3)
prior nephrectomy
no 4 (26.7)
Yes 11 (73.3)
Metastatic site
Bone 4 (26.7)
Brain 1 (6.7)
liver 8 (53.3)
lung 7 (46.7)
lymph node 15 (100.0)
Other 12 (80.0)
Notes: Data are n (%) unless noted. aeCOG pS from case report forms; last 
measure taken before dosing on or before randomization date. bMSKCC risk groups 
were classified using the following three risk factors: low serum hemoglobin (less 
than the lower limit of normal), high corrected serum calcium (.10 mg/dl), and 
eCOG pS (0 versus 1).38
Abbreviations: eCOG pS, eastern Cooperative Oncology Group performance 
status; MSKCC, Memorial Sloan-Kettering Cancer Center.
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(range: 3.5–645.0 days). The median daily dose was 13.5 mg 
(range: 4.33–19.27 mg). Thirteen (86.7%) patients had their 
daily dose increased .10 mg for at least two consecutive 
doses at any time during the study. Five (33.3%) patients had 
their daily dose reduced ,10 mg for at least two consecutive 
doses at any time during the study.
Efficacy
Two (13.3%) patients had a confirmed partial response 
as assessed by the investigator using RECIST compared 
with nine (60.0%) patients when Choi criteria were applied 
(Table 3). Of the nine patients who had partial response per 
Choi, RECIST criteria categorized two with partial response, 
four with stable disease, one with indeterminate response, 
and two with progressive disease. No complete responses 
were reported with either criteria, four patients had stable 
disease and six patients had progressive disease per RECIST, 
whereas no patient had stable disease and three patients had 
progressive disease per Choi criteria (Table 3). Six (40.0%) 
patients had a clinical benefit according to RECIST. Nine 
(60%) events of progression or death were reported at study 
end and three patients continued on study drug. A median PFS 
of 2.5 months (95% CI: 1.7 – not estimable; Figure 1) was 
observed. The estimated survival probability at 12 months 
was 57.8% (95% CI: 29.0–78.4). Eight patients were alive 
at the time of study closure and were not followed-up further 
for OS, thus limiting further interpretation of OS data.
Safety
Treatment-emergent AEs (TEAEs) are shown in Table 4. 
Overall, 15 (100%) patients experienced a total of 176 TEAEs. 
Six (40.0%) patients experienced treatment-emergent seri-
ous AEs; four (26.7%) experienced treatment-emergent, 
treatment-related serious AEs. Three (20.0%) patients 
discontinued treatment due to TEAEs. The most common 
all-grade, all-causality TEAEs (% patients) were fatigue 
(73.3%), diarrhea (60.0%), and decreased appetite (53.3%). 
The most common grade $3 all-causality TEAEs were 
fatigue (33.3%) and diarrhea (20.0%). Seven (46.7%) 
patients died during the study: one (6.7%) patient during 
treatment and six (40.0%) patients during follow-up. The 
cause of death in all cases was mRCC related. No patients had 
Table 3 Best response according to reCiST and Choi criteria 
following treatment with axitinib: full analysis set
Objective tumor response n (%)
RECIST 1.1 Choi
patients with baseline assessment 15 (100) 15 (100)
patients with measurable disease 
at baseline
15 (100) 15 (100)
Best overall response
Complete response 0 0
partial response 2 (13.3) 9 (60.0)
Stable disease 4 (26.7) 0
progressive disease 6 (40.0) 3 (20.0)
not assessed 1 (6.7) 1 (6.7)
early death 0 1 (6.7)
indeterminate 2 (13.3) 1 (6.7)
Overall confirmed ORR (complete 
response + partial response)
2 (13.3) 9 (60.0)
95% exact Cia 1.7%–40.5% 16.3%–67.7%
Note: aUsing exact method based on binomial distribution.
Abbreviations: reCiST, response evaluation Criteria in Solid Tumors; Orr, 
overall response rate; CI, confidence interval.
Figure 1 Kaplan–Meier curve estimate for progression-free survival (derived investigator’s assessment): full analysis set.
Abbreviations: NE, not estimable; PFS, progression-free survival; CI, confidence interval.
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arterial thromboembolic events, gastrointestinal perforation, 
hemorrhage, hepatic disorders, or venous thrombolic events. 
No patients had AEs related to hematology parameters. One 
(6.7%) patient had an AE related to chemistry parameters 
(grade 2 hypercalcemia) and two (13.3%) had AEs related 
to urinalysis parameters (grade 3 proteinuria). Two (13.3%) 
patients had grade 1 hyperthyroidism, one (6.7%) had grade 2 
hyperthyroidism, one (6.7%) had grade 1 blood thyroid-
stimulating hormone increase, and one (6.7%) patient had 
grade 1 abnormal thyroid function test.
patient-reported outcomes
Mean EQ-5D score at baseline was 0.7947, and mean change 
from baseline to end of treatment was −0.0837. Mean Euro-
Qol Visual Analogue Scale score at baseline was 73.3, and 
mean change from baseline to end of treatment was −6.5.
Discussion
Although limited by the small number of patients and the 
lack of a reference arm, the efficacy results observed in previ-
ously treated Canadian and Australian patients with mRCC 
treated with axitinib in the current study are consistent with 
previous studies18,29–31 and provide further support for the use 
of axitinib in patients with mRCC whose disease progressed 
after one prior systemic therapy.
Response rate following axitinib treatment was higher 
using Choi criteria than RECIST criteria. These results are 
consistent with previous studies in patients with metastatic 
GIST, where more patients were responders by Choi than 
by RECIST criteria, respectively, after treatment with ima-
tinib (84% versus 48%)21 or sunitinib (31% versus 2%).32 
Studies in patients with hepatocellular carcinoma also 
showed that more patients met Choi response criteria than 
RECIST, respectively, after treatment with transarterial 
radioembolization (78% versus 22%)25 or sorafenib (38% 
versus 15%).33 However, there are contradicting results 
regarding the ability of Choi criteria to better predict thera-
peutic benefit than RECIST. One study in GIST showed that 
responders by Choi criteria were correlated with significantly 
longer time to progression and disease-specific survival than 
nonresponders, whereas by RECIST, responders were not 
significantly correlated with time to progression or disease-
specific survival compared with nonresponders.21 Similarly, 
a study in hepatocellular carcinoma showed that responders 
according to Choi criteria had a significantly longer time 
to progression (median: 280 days versus 166 days) and OS 
(median: 442 days versus 247 days) than nonresponders, 
respectively, whereas based on RECIST, responders did not 
have improved time to progression or OS compared with 
nonresponders.25 However, other studies in GIST and in high-
grade soft-tissue sarcomas demonstrated that although more 
patients had response based on Choi criteria compared with 
RECIST, the absence of progression (partial response plus 
stable disease) was the most important predictive marker of 
therapeutic benefit regardless of response criteria used.26,32
Choi criteria have not been studied widely in the context 
of mRCC and ours is the first study of axitinib administered 
as second-line treatment in patients with mRCC whose tumor 
responses were evaluated using both RECIST 1.1 and Choi 
criteria. A previous study in patients with mRCC treated with 
sunitinib showed that at first evaluation, more patients experi-
enced tumor response based on Choi versus RECIST criteria, 
respectively (partial response: n=36 versus 7; stable disease: 
n=6 versus 38; and progressive disease: n=13 versus 10).27 
Furthermore, at first evaluation, response by Choi criteria 
was a significantly better predictor of PFS and OS than 
response by RECIST. However, when best response (partial 
response plus stable disease $12 weeks) was taken into 
account, Choi criteria were not superior to RECIST criteria 
in predicting PFS or OS in patients with mRCC treated with 
sunitinib.27 Results from our study, albeit small, are in line 
with most of the published data. As predicted, there were a 
higher number of patients with partial response when Choi 
criteria were applied. This is understandable, as the decreased 
Table 4 Treatment-emergent, all-causality adverse events 
experienced by .10% of patients
MedDRA preferred term Axitinib, N=15, n (%)
All grades Grade $3
Fatigue 11 (73.3) 5 (33.3)
Diarrhea 9 (60.0) 3 (20.0)
Decreased appetite 8 (53.3) 2 (13.3)
Hypertension 6 (40.0) 2 (13.3)
nausea 5 (33.3) 1 (6.7)
Weight decrease 5 (33.3) 1 (6.7)
arthralgia 4 (26.7) 0
Back pain 4 (26.7) 1 (6.7)
ppe 4 (26.7) 1 (6.7)
Hyperthyroidism 3 (20.0) 0
Muscle spasms 3 (20.0) 1 (6.7)
Dysphonia 3 (20.0) 0
proteinuria 2 (13.3) 2 (13.3)
Dysphagia 2 (13.3) 1 (6.7)
Vomiting 2 (13.3) 0
Mucosal inflammation 2 (13.3) 0
Upper respiratory tract infection 2 (13.3) 0
Muscular weakness 2 (13.3) 0
Dizziness 2 (13.3) 0
Headache 2 (13.3) 0
rash 2 (13.3) 0
Abbreviations: MedDra, Medical Dictionary for regulatory activities v16.1 
coding dictionary; ppe, palmar-plantar erythrodysesthesia.
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vascularity or necrotic tumor cells within the target lesion 
may not immediately result in a change in size; however, 
they would have a different density that can be accurately 
checked if Choi criteria are used. In some cases, this may 
mean an underevaluation of clinical benefit and a premature 
discontinuation of treatment for the patient.
Maintaining the highest possible QoL is another goal for 
the treatment of mRCC. Patients treated with axitinib were 
generally able to maintain QoL while on treatment, before 
their disease progressed. No new safety concerns were identi-
fied, and the most commonly reported AEs (fatigue, diarrhea, 
and decreased appetite) were consistent with those reported 
previously in patients with mRCC treated with axitinib18,29,30,34 
or other inhibitors of the VEGF pathway.6,35–37
The results from this study should be viewed with respect 
to its limitations. This was a single-arm study with a small 
number of patients; therefore, data observed in this study 
had to be compared with efficacy and safety profiles of 
axitinib observed in previous clinical studies. Also, tumor 
response was assessed by the study radiologists and not by 
an independent review committee. In addition, the study 
ended prematurely, and patients were not followed-up for 
survival for up to 2 years, as planned, but only until the end 
date of the study.
Conclusion
This study provided early access to axitinib for Australian and 
Canadian patients who failed one prior therapy for mRCC. 
The small number of patients and the lack of a reference arm 
in this study limit the ability to draw definitive conclusions. 
However, the safety and efficacy profiles of axitinib in this 
study were consistent with those seen in previous studies in 
patients with mRCC and generally enabled patients to main-
tain QoL. The sizeable difference observed in ORR between 
RECIST and Choi criteria (13% versus 60%, respectively) 
indicates that the use of Choi criteria to assess tumor response 
in patients with mRCC merits further research in a larger, 
prospective, and randomized study.
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